iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference
iCAD, a leader in AI-powered breast health solutions, announced its participation in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, at the Sheraton New York Times Square Hotel. CEO Dana Brown and CFO Eric Lonnqvist will be available for one-on-one meetings during the event.
The conference serves as an idea generation platform for institutional investors, featuring over 90 selected companies with market caps under $500 million. Selected companies demonstrate characteristics such as attractive business models, strong management, competitive advantages, unique solutions, and growth prospects.
iCAD, leader nelle soluzioni per la salute del seno basate sull'intelligenza artificiale, ha annunciato la sua partecipazione alla 15ª Conferenza Annuale Craig-Hallum Alpha Select che si terrà il 19 novembre 2024 presso il Sheraton New York Times Square Hotel. Il CEO Dana Brown e il CFO Eric Lonnqvist saranno disponibili per incontri individuali durante l'evento.
La conferenza funge da piattaforma per la generazione di idee per investitori istituzionali, presentando oltre 90 aziende selezionate con capitalizzazioni di mercato inferiori ai 500 milioni di dollari. Le aziende selezionate dimostrano caratteristiche come modelli di business attraenti, una forte gestione, vantaggi competitivi, soluzioni uniche e prospettive di crescita.
iCAD, líder en soluciones de salud mamaria impulsadas por inteligencia artificial, anunció su participación en la 15ª Conferencia Anual Craig-Hallum Alpha Select el 19 de noviembre de 2024, en el Sheraton New York Times Square Hotel. El CEO Dana Brown y el CFO Eric Lonnqvist estarán disponibles para reuniones individuales durante el evento.
La conferencia sirve como una plataforma para la generación de ideas para inversores institucionales, contando con más de 90 empresas seleccionadas que tienen capitalizaciones de mercado inferiores a 500 millones de dólares. Las empresas seleccionadas demuestran características como modelos de negocio atractivos, una gestión sólida, ventajas competitivas, soluciones únicas y perspectivas de crecimiento.
iCAD는 인공지능 기반의 유방 건강 솔루션 분야의 선두주자로서 제15회 Craig-Hallum Alpha Select 컨퍼런스에 참가할 예정이라고 발표했습니다. 이 행사는 2024년 11월 19일 뉴욕 타임스 스퀘어의 Sheraton 호텔에서 진행됩니다. CEO Dana Brown과 CFO Eric Lonnqvist는 행사 동안 일대일 미팅을 진행할 수 있습니다.
이 컨퍼런스는 기관 투자자들을 위한 아이디어 생성 플랫폼으로, 5억 달러 미만의 시장가치를 가진 90개 이상의 선정된 기업을 소개합니다. 선정된 기업들은 매력적인 비즈니스 모델, 강력한 경영, 경쟁 우위, 독창적인 솔루션 및 성장 전망과 같은 특성을 나타냅니다.
iCAD, un leader dans les solutions de santé mammaire alimentées par l'intelligence artificielle, a annoncé sa participation à la 15ème Conférence Annuelle Craig-Hallum Alpha Select qui se déroulera le 19 novembre 2024 à l'hôtel Sheraton New York Times Square. Le PDG Dana Brown et le directeur financier Eric Lonnqvist seront disponibles pour des réunions individuelles pendant l'événement.
La conférence sert de plateforme de génération d'idées pour les investisseurs institutionnels, présentant plus de 90 entreprises sélectionnées ayant des capitalisations boursières inférieures à 500 millions de dollars. Les entreprises sélectionnées montrent des caractéristiques telles que des modèles d'affaires attrayants, une gestion solide, des avantages concurrentiels, des solutions uniques et des perspectives de croissance.
iCAD, ein führendes Unternehmen im Bereich KI-gestützter Brustgesundheitslösungen, hat seine Teilnahme an der 15. jährlichen Craig-Hallum Alpha Select Konferenz am 19. November 2024 im Sheraton New York Times Square Hotel bekannt gegeben. CEO Dana Brown und CFO Eric Lonnqvist werden während der Veranstaltung für persönliche Treffen zur Verfügung stehen.
Die Konferenz dient als Ideenplattform für institutionelle Investoren und stellt über 90 ausgewählte Unternehmen mit Marktkapitalisierungen unter 500 Millionen Dollar vor. Die ausgewählten Unternehmen weisen Merkmale wie attraktive Geschäftsmodelle, starkes Management, Wettbewerbsvorteile, einzigartige Lösungen und Wachstumsperspektiven auf.
- None.
- None.
NASHUA, N.H., Nov. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 at the Sheraton New York Times Square Hotel in New York City, New York. Management will be available for one-on-one meetings throughout the day. To request a meeting with iCAD, investors should contact their Craig-Hallum representative.
The Craig-Hallum Alpha Select Conference is an idea generation opportunity for institutional investors. More than 90 public companies have been selected to present by the Craig-Hallum research team based on characteristics that are consistent with the firm’s Alpha Select List. These include a sub-
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACTS
Media inquiries:
pr@icadmed.com
Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com
FAQ
When is iCAD (ICAD) attending the Craig-Hallum Alpha Select Conference in 2024?
Which iCAD executives are attending the Craig-Hallum Conference 2024?
What are the selection criteria for companies at the Craig-Hallum Alpha Select Conference?
How many companies are presenting at the 15th Annual Craig-Hallum Conference?
